Delivery Order SPE2DB24D2205-SPE2DB25FEFPU
- Not listed
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of CellCept 500 mg tablets. The contract has a ceiling value of $9,014.61 and a period of performance through April 9, 2025. AmerisourceBergen, the prime contractor, has no set-aside designation, indicating open competition. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at...
- The Defense Logistics Agency awarded a delivery order valued at $35,063.75 to AmerisourceBergen Drug Corp for 100 tablets of CellCept 500 mg, with an ultimate completion date of July 28, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is classified as a delivery order under a larger contract vehicle. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains...
- This is a $3,404.38 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The order is for the supply of 100 units of the prescription medication CellCept 250 mg capsules. The delivery order has a completion date of May 13, 2025. AmerisourceBergen Drug Corp holds a large $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $28,043.16, is for the delivery of CellCept 500 mg tablets over a period ending on May 8, 2025. CellCept is an immunosuppressant medication used to prevent organ rejection in transplant patients. The contract is not a set-aside and was openly competed. AmerisourceBergen Drug Corp holds a larger Indefinite...
- This is a $11,150.93 firm-fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of CELLCEPT 500 MG TABLET 500S. The contract has an ultimate completion date of June 30, 2025 and is not designated as a set-aside. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which provides a comprehensive global...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $12,036.59, is for the delivery of CELLCEPT 500 MG TABLET 500S, a pharmaceutical product, with a completion date of May 20, 2025. The award is not set aside and involves open competition. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC)...
- This is a $55,214.59 firm fixed-price delivery order contract awarded to Amerisourcebergen Drug Corp by the Defense Logistics Agency (DLA) for CELLCEPT 500 MG TABLET 500S. The contract has an ultimate completion date of June 17, 2025. Amerisourcebergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, providing a comprehensive global pharmaceutical support...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of CELLCEPT 500 MG TABLET 100S. The contract has a firm fixed price of $8,112.06 and a completion date of June 17, 2025. It is not designated as a set-aside contract, indicating open competition. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00,...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of CellCept 500 mg tablets, a medication used for organ transplant patients. The contract has a firm fixed price of $8,292.86 and a period of performance through February 14, 2025. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical worth...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $85,073.04, is for the delivery of CELLCEPT 500 MG TABLET 500S, a pharmaceutical product, with a performance period through May 1, 2025. The contract is not set aside for any specific business type. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with...
- SPE2DB24D2205Indefinite Delivery Contract
- SPE2DB24D2205-SPE2DB25FEFPUDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of CellCept 500 mg tablets (500-count bottles) under a firm fixed-price contract with a ceiling value of $13,051.42. The delivery order, which is not set-aside, is scheduled for completion by July 31, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, has been competitively selected to fulfill this pharmaceutical supply requirement. The company serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the DLA Medical Supply Chain. CellCept, an immunosuppressant medication, supports the broad pharmaceutical portfolio deliverable under the parent IDC, which encompasses specialty medications, brand-name and generic drugs, vaccines, and other medical supplies across multiple therapeutic domains to support military healthcare programs worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.1k | 7/30/25 |